Citius Pharmaceuticals Inc CTXR

NAS: CTXR | ISIN: US17322U2078   30/04/2025
0,765 USD (+0,35%)
(+0,35%)   30/04/2025

1 april 2025 · Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock · Persbericht

5 september 2024 · Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

5 september 2024 · Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology · Persbericht

12 augustus 2024 · Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update · Persbericht

12 augustus 2024 · Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. · Persbericht

12 augustus 2024 · Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments · Persbericht

8 augustus 2024 · Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma · Persbericht

5 augustus 2024 · Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. · Persbericht

10 juli 2024 · Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates · Persbericht

29 mei 2024 · Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution · Persbericht

21 mei 2024 · Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution · Persbericht

14 mei 2024 · Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

10 mei 2024 · Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences · Persbericht

30 april 2024 · Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering · Persbericht

26 april 2024 · Citius Pharmaceuticals Announces $15 Million Registered Direct Offering · Persbericht

11 april 2024 · Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma · Persbericht

4 april 2024 · Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference · Persbericht

18 maart 2024 · Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma · Persbericht

7 maart 2024 · Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program · Persbericht

26 februari 2024 · Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration · Persbericht

Mijn selecties